BDNF variability in opioid addicts and response to methadone treatment

Preliminary findings

R. De Cid, F. Fonseca, M. Gratacòs, F. Gutierrez, R. Martín-Santos, Xavier P. Estivill, M. Torrens

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Brain-derived neurotrophic factor (BDNF) signaling pathways have been shown to be essential for opioid-induced plasticity. We conducted an exploratory study to evaluate BDNF variability in opioid addict responders and nonresponders to methadone maintenance treatment (MMT). We analyzed 21 single nucleotide polymorphisms (SNPs) across the BDNF genomic region. Responders and nonresponders were classified by means of illicit opioid consumption detected in random urinalysis. Patients were assessed by a structured interview (Psychiatric Research Interview for Substance and Mental Disorders (PRISM)-DSM-IV) and personality was evaluated by the Cloninger's Temperament and Character Inventory. No clinical, environmental and treatment characteristics were different between the groups, except for the Cooperativeness dimension (P < 0.001). Haplotype block analysis showed a low-frequency (2.7%) haplotype (13 SNPs) in block 1, which was more frequent in the nonresponder group than in the responder group (4/42 vs. 1/135; Pcorrected = 0.023). Fine mapping in block 1 allows us to identify a haplotype subset formed by only six SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119) associated with differential response to MMT (global P sim = 0.011). Carriers of the CCGCCG haplotype had an increased risk of poorer response, even after adjusting for Cooperativeness score (OR = 20.25 95% CI 1.46-280.50, P = 0.025). These preliminary results might suggest the involvement of BDNF as a factor to be taken into account in the response to MMT independently of personality traits, environmental cues, methadone dosage and psychiatric comorbidity.

Original languageEnglish
Pages (from-to)515-522
Number of pages8
JournalGenes, Brain and Behavior
Volume7
Issue number5
DOIs
Publication statusPublished - Jul 2008
Externally publishedYes

Fingerprint

Methadone
Brain-Derived Neurotrophic Factor
Haplotypes
Opioid Analgesics
Single Nucleotide Polymorphism
Psychiatry
Personality
Interviews
Urinalysis
Temperament
Therapeutics
Mental Disorders
Diagnostic and Statistical Manual of Mental Disorders
Cues
Comorbidity
Equipment and Supplies
Research

Keywords

  • ASI
  • BDNF
  • Methadone
  • Opioid dependence
  • Pharmacogenetics
  • PRISM
  • Substance abuse
  • TCI

ASJC Scopus subject areas

  • Neuroscience(all)
  • Genetics

Cite this

BDNF variability in opioid addicts and response to methadone treatment : Preliminary findings. / De Cid, R.; Fonseca, F.; Gratacòs, M.; Gutierrez, F.; Martín-Santos, R.; Estivill, Xavier P.; Torrens, M.

In: Genes, Brain and Behavior, Vol. 7, No. 5, 07.2008, p. 515-522.

Research output: Contribution to journalArticle

De Cid, R, Fonseca, F, Gratacòs, M, Gutierrez, F, Martín-Santos, R, Estivill, XP & Torrens, M 2008, 'BDNF variability in opioid addicts and response to methadone treatment: Preliminary findings', Genes, Brain and Behavior, vol. 7, no. 5, pp. 515-522. https://doi.org/10.1111/j.1601-183X.2007.00386.x
De Cid, R. ; Fonseca, F. ; Gratacòs, M. ; Gutierrez, F. ; Martín-Santos, R. ; Estivill, Xavier P. ; Torrens, M. / BDNF variability in opioid addicts and response to methadone treatment : Preliminary findings. In: Genes, Brain and Behavior. 2008 ; Vol. 7, No. 5. pp. 515-522.
@article{a37f81f8ad3f4747a8f0d47ea5e0d3ca,
title = "BDNF variability in opioid addicts and response to methadone treatment: Preliminary findings",
abstract = "Brain-derived neurotrophic factor (BDNF) signaling pathways have been shown to be essential for opioid-induced plasticity. We conducted an exploratory study to evaluate BDNF variability in opioid addict responders and nonresponders to methadone maintenance treatment (MMT). We analyzed 21 single nucleotide polymorphisms (SNPs) across the BDNF genomic region. Responders and nonresponders were classified by means of illicit opioid consumption detected in random urinalysis. Patients were assessed by a structured interview (Psychiatric Research Interview for Substance and Mental Disorders (PRISM)-DSM-IV) and personality was evaluated by the Cloninger's Temperament and Character Inventory. No clinical, environmental and treatment characteristics were different between the groups, except for the Cooperativeness dimension (P < 0.001). Haplotype block analysis showed a low-frequency (2.7{\%}) haplotype (13 SNPs) in block 1, which was more frequent in the nonresponder group than in the responder group (4/42 vs. 1/135; Pcorrected = 0.023). Fine mapping in block 1 allows us to identify a haplotype subset formed by only six SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119) associated with differential response to MMT (global P sim = 0.011). Carriers of the CCGCCG haplotype had an increased risk of poorer response, even after adjusting for Cooperativeness score (OR = 20.25 95{\%} CI 1.46-280.50, P = 0.025). These preliminary results might suggest the involvement of BDNF as a factor to be taken into account in the response to MMT independently of personality traits, environmental cues, methadone dosage and psychiatric comorbidity.",
keywords = "ASI, BDNF, Methadone, Opioid dependence, Pharmacogenetics, PRISM, Substance abuse, TCI",
author = "{De Cid}, R. and F. Fonseca and M. Gratac{\`o}s and F. Gutierrez and R. Mart{\'i}n-Santos and Estivill, {Xavier P.} and M. Torrens",
year = "2008",
month = "7",
doi = "10.1111/j.1601-183X.2007.00386.x",
language = "English",
volume = "7",
pages = "515--522",
journal = "Genes, Brain and Behavior",
issn = "1601-1848",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - BDNF variability in opioid addicts and response to methadone treatment

T2 - Preliminary findings

AU - De Cid, R.

AU - Fonseca, F.

AU - Gratacòs, M.

AU - Gutierrez, F.

AU - Martín-Santos, R.

AU - Estivill, Xavier P.

AU - Torrens, M.

PY - 2008/7

Y1 - 2008/7

N2 - Brain-derived neurotrophic factor (BDNF) signaling pathways have been shown to be essential for opioid-induced plasticity. We conducted an exploratory study to evaluate BDNF variability in opioid addict responders and nonresponders to methadone maintenance treatment (MMT). We analyzed 21 single nucleotide polymorphisms (SNPs) across the BDNF genomic region. Responders and nonresponders were classified by means of illicit opioid consumption detected in random urinalysis. Patients were assessed by a structured interview (Psychiatric Research Interview for Substance and Mental Disorders (PRISM)-DSM-IV) and personality was evaluated by the Cloninger's Temperament and Character Inventory. No clinical, environmental and treatment characteristics were different between the groups, except for the Cooperativeness dimension (P < 0.001). Haplotype block analysis showed a low-frequency (2.7%) haplotype (13 SNPs) in block 1, which was more frequent in the nonresponder group than in the responder group (4/42 vs. 1/135; Pcorrected = 0.023). Fine mapping in block 1 allows us to identify a haplotype subset formed by only six SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119) associated with differential response to MMT (global P sim = 0.011). Carriers of the CCGCCG haplotype had an increased risk of poorer response, even after adjusting for Cooperativeness score (OR = 20.25 95% CI 1.46-280.50, P = 0.025). These preliminary results might suggest the involvement of BDNF as a factor to be taken into account in the response to MMT independently of personality traits, environmental cues, methadone dosage and psychiatric comorbidity.

AB - Brain-derived neurotrophic factor (BDNF) signaling pathways have been shown to be essential for opioid-induced plasticity. We conducted an exploratory study to evaluate BDNF variability in opioid addict responders and nonresponders to methadone maintenance treatment (MMT). We analyzed 21 single nucleotide polymorphisms (SNPs) across the BDNF genomic region. Responders and nonresponders were classified by means of illicit opioid consumption detected in random urinalysis. Patients were assessed by a structured interview (Psychiatric Research Interview for Substance and Mental Disorders (PRISM)-DSM-IV) and personality was evaluated by the Cloninger's Temperament and Character Inventory. No clinical, environmental and treatment characteristics were different between the groups, except for the Cooperativeness dimension (P < 0.001). Haplotype block analysis showed a low-frequency (2.7%) haplotype (13 SNPs) in block 1, which was more frequent in the nonresponder group than in the responder group (4/42 vs. 1/135; Pcorrected = 0.023). Fine mapping in block 1 allows us to identify a haplotype subset formed by only six SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119) associated with differential response to MMT (global P sim = 0.011). Carriers of the CCGCCG haplotype had an increased risk of poorer response, even after adjusting for Cooperativeness score (OR = 20.25 95% CI 1.46-280.50, P = 0.025). These preliminary results might suggest the involvement of BDNF as a factor to be taken into account in the response to MMT independently of personality traits, environmental cues, methadone dosage and psychiatric comorbidity.

KW - ASI

KW - BDNF

KW - Methadone

KW - Opioid dependence

KW - Pharmacogenetics

KW - PRISM

KW - Substance abuse

KW - TCI

UR - http://www.scopus.com/inward/record.url?scp=47249097896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249097896&partnerID=8YFLogxK

U2 - 10.1111/j.1601-183X.2007.00386.x

DO - 10.1111/j.1601-183X.2007.00386.x

M3 - Article

VL - 7

SP - 515

EP - 522

JO - Genes, Brain and Behavior

JF - Genes, Brain and Behavior

SN - 1601-1848

IS - 5

ER -